Loading stock data…
AYTU
$2.61+0.01 (+0.38%)
Market ClosedLast close May 1
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aytu BioPharma, Inc. in the Healthcare sector is trading at $2.61. The stock is currently 15% below its 52-week high of $3.07, remaining 8.8% above its 200-day moving average. Technical signals show neutral RSI of 48 and bullish MACD crossover, explaining why AYTU maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.61
Potential Upside
5%
Whystock Fair Value$2.74
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), inc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$27.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-109.23%
Volume
Today's trading volume
28,273
Recent News
Favourable Signals For Aytu BioPharma: Numerous Insiders Acquired Stock
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Shift From Loss To Profit
With the business potentially at an important milestone, we thought we'd take a closer look at Aytu BioPharma, Inc.'s...
Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navigating Challenges and ...
Aytu BioPharma Inc (AYTU) reports a mixed quarter with decreased revenues but a promising start for its novel depression treatment, EXXUA.
Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates
Aytu BioPharma (AYTU) delivered earnings and revenue surprises of -303.85% and +26.27%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for February 2nd
AAWH, AYTU and BCAL have been added to the Zacks Rank #5 (Strong Sell) List on February 2, 2026.